Asymptomatic hyperammonemia in children treated with valproic acid

Journal of Child Neurology

Volumn 12, Issue 7, 1997, Pages 461-463

  Altunbaşak, Şakir ^a   Baytok, Vildan ^a   Tasouji, Mehdi ^a   Hergüner, Özlem ^a   Burgut, Refik ^a   Kayrin, Levent ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CARNITINE; CLONAZEPAM; LAMOTRIGINE; PHENOBARBITAL; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AMMONIA BLOOD LEVEL; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CONTROLLED STUDY; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HUMAN; HYPERAMMONEMIA; INFANT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0031454914     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307389701200709     Document Type: Article

References (24)

1. Halmagyi GM, Rudge P, Gresty MA, et al: Treatment of periodic alternating nystagmus. Ann Neurol 1980;8:609-611.
2. Leigh RJ, Zee DS: The Neurology of Eye Movements. Philadelphia, FA Davis Co, 1983, pp 203-205.
3. Young RSK, Bergman I, Gang DI, et al: Fetal Reye-like syndrome associated with valproic acid. Ann Neurol 1980;7:389.
4. Coulter DL, Allen RJ: Pancreatitis associated with valproic acid therapy for epilepsy. Ann Neurol 1980:7;92.
5. Marescaux C, Water JM, Micheletti G, et al: Stuporous episodes during treatment with sodium valproate: Report of seven cases. Epilepsia 1982;23:297-305.
6. Gago MC, Novo I, Segade SR: Effects of valproic acid on the urea cycle and carnitine metabolism. Int Pediatr 1990;5:54-57.
7. Matsuda I, Ohtani Y, Ninomiya N: Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr 1986;109:131-134.
8. Ohtani Y, Endo F, Matsuda I: Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982;101: 782-785.
9. Walheim DF: The significance of the hydrogen ion concentration and the addition of ADF in the determination of ammonia. Z Klin Chim Klin Biochim 1973;11:421-426.
10. SPSS-X, User's Guide. Chicago, SPSS Co Inc, 1985.
11. Schobben F, Van der Klein E, Gabreels FJM: Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol 1975;8: 97-105.
12. Thom H, Carter PE, Cole GF, et al: Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol 1991;33:795-802.
13. Ratnike RN, Schapel GJ, Purdie G, et al: Hyperammonemia and hepatotoxicity during chronic valproate therapy: Enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 1986;22: 100-103.
14. Haidukewyech D, John G, Zielinski JJ, et al: Chronic valproic acid therapy and incidence of increase in venous plasma ammonia. Ther Drug Monit 1985;7:290-294.
15. Zaccara G, Campostrini R, Paganini CM, et al: Long-term treatment with sodium valproate: Monitoring of venous ammonia concentrations and adverse effects. Ther Drug Monit 1987;9:34-40.
16. Walter JM, Marescaux C, Brandt C: Sodium-valproate associated with phenobarbital: Effects of ammonia metabolism in humans. Epilepsia 1983;24:628-633.
17. Laub MC: Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 1986;27:55-59.
18. Coulter DL, Allen RJ, Arbor A: Hyperammonemia with valproic acid therapy. J Pediatr 1981;99:317-319.
19. Marescaux C, Warter JM, Laroye M, et al: Le valproate de sodium: une droge hyperammonemiante. J Neurol Sci 1983;58:195-209.
20. Marini AN, Zaret BS, Beckner RR, et al: Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology 1988;38: 365-370.
21. Warter JM, Marescaux C, Chabrier G, et al: Increased of valproate induced hyperammonemia in normal subjects by carbonhydrate intake. Neurology 1984;34:1487-1489.
22. Thurston JH, Hauhart RE, Carroll JE, et al: A single therapeutic dose of valproate affects liver, carbohydrate, fat, adenylate, amino acid, coenzyme-A(CoA) and carnitine metabolism in infant mice: Possible clinical significance. Life Sci 1985;36:1643-1651.
23. Thurston JH, Hauhart RE, Carroll JE, et al: Single doses of valproate reduce ketonemia in infant mice: Reversal by L-carnitine. Pediatr Res 1984;18:383A.
24. Melegh BB, Kerner J, Acsadi G, et al: L-carnitine replacement therapy in chronic valproate treatment. Neuropediatrics 1990;21:40-43.